ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors-Reference-Cited by-同舟云学术

ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors

Published:2019-12-03 Issue:2 Volume:250 Page:159-169
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Kaipio Katja¹^ORCID,Chen Ping²,Roering Pia¹,Huhtinen Kaisa¹,Mikkonen Piia³,Östling Päivi⁴⁵,Lehtinen Laura¹,Mansuri Naziha¹,Korpela Taina¹,Potdar Swapnil⁶,Hynninen Johanna⁷,Auranen Annika⁸,Grénman Seija⁷,Wennerberg Krister⁶⁹,Hautaniemi Sampsa¹⁰^ORCID,Carpén Olli¹¹⁰^ORCID

Affiliation:

1. Research Center for Cancer, Infections and Immunity, Institute of Biomedicine University of Turku Turku Finland

2. Integrated Cardio Metabolic Centre (ICMC), Department of Medicine Karolinska Institutet Huddinge Sweden

3. Institute for Molecular Medicine Finland, HiLIFE University of Helsinki Helsinki Finland

4. Science for Life Laboratory Department of Oncology & Pathology Karolinska Institutet Huddinge Sweden

5. Institute for Molecular Medicine Finland, FIMM University of Helsinki Helsinki Finland

6. Institute for Molecular Medicine Finland, High Throughput Biomedicine Unit (HTB) University of Helsinki Helsinki Finland

7. Department of Obstetrics and Gynaecology University of Turku and Turku University Hospital Turku Finland

8. Department of Obstetrics and Gynaecology University of Tampere and Tampere University Hospital Tampere Finland

9. Biotech Research & Innovation Centre (BRIC) University of Copenhagen Copenhagen Denmark

10. Research Programs Unit, Genome‐Scale Biology and Medicum, Faculty of Medicine University of Helsinki Helsinki Finland

Funder

Academy of Finland

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/path.5356

Reference54 articles.

1. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

2. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

3. Cancer stem cells: implications for cancer therapy;Dawood S;Oncology (Williston Park),2014

4. Ovarian cancer stem cells: Working towards the root of stemness

5. A more efficient method to generate integration-free human iPS cells

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-ciliated tubal epithelial cells are prone to initiation of high-grade serous ovarian carcinoma;2023-12-13

2. Cancer Stem Cell Markers—Clinical Relevance and Prognostic Value in High-Grade Serous Ovarian Cancer (HGSOC) Based on The Cancer Genome Atlas Analysis;International Journal of Molecular Sciences;2023-08-13

3. Tumor-Associated Macrophages Expand Chemoresistant, Ovarian Cancer Stem-Like Cells;2023-07-19

4. Emerging roles of Aurora-A kinase in cancer therapy resistance;Acta Pharmaceutica Sinica B;2023-07

5. Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma;Cancer Cell;2023-06